FDA Approves LAMOTRIGINE KIT — OWP Pharmaceuticals, Inc.

OWP Pharmaceuticals, Inc. received FDA approval for its multi-strength Lamotrigine oral kit, marking its entry into the antiepileptic market and enabling the company to compete with existing branded competitors. This clearance is anticipated to drive pricing pressure and erode market share occupied by branded drugs in the neurological category.